Received 23 September 1997/Returned for modification 16 January 1998/Accepted 19 February 1998
|
|
- Dominic Baldwin
- 5 years ago
- Views:
Transcription
1 JOURNAL OF CLINICAL MICROBIOLOGY, June 1998, p Vol. 36, No /98/$ Copyright 1998, American Society for Microbiology Comparison of Performances of Two Commercially Available Tests, a PCR Assay and a Ligase Chain Reaction Test, in Detection of Urogenital Chlamydia trachomatis Infection MIRJA PUOLAKKAINEN, 1 * EIJA HILTUNEN-BACK, 2 TIMO REUNALA, 2 SATU SUHONEN, 3 PEKKA LÄHTEENMÄKI, 3 MATTI LEHTINEN, 4 AND JORMA PAAVONEN 5 Haartman Institute, Department of Virology, 1 and Departments of Dermatology and Venereology 2 and Obstetrics and Gynecology, 5 University of Helsinki, Family Federation of Finland, 3 and Department of Infectious Disease Epidemiology, National Public Health Institute, 4 Helsinki, Finland Received 23 September 1997/Returned for modification 16 January 1998/Accepted 19 February 1998 The diagnostic performance of a PCR test (Roche Cobas Amplicor CT/NG Test) and that of a ligase chain reaction (LCR) test (Abbott LCx Chlamydia trachomatis assay) were compared by using endocervical and urethral swab specimen culture as a reference test. First-void urine (FVU) and endocervical and urethral swab specimens were collected from 1,015 unselected patients attending a sexually transmitted disease clinic and a clinic for adolescents in Helsinki, Finland. Chlamydia trachomatis was cultured from samples from the endocervix or urethra. PCR was performed with fresh and frozen urine and the culture transport medium. LCR was performed with fresh and frozen urine and LCx swab transport medium. Diagnostic consistency and diagnostic accuracy were statistically tested. The test results were identical for 984 patients (97%). Discrepant results were observed for 31 patients. Overall, LCR and PCR showed excellent kappa coefficients of consistency for both swab and FVU specimens (0.93 and 0.95, respectively). Sixty-one patients (6%) were culture positive. Testing of FVU by LCR or PCR increased the overall positivity rates to 7.0 and 7.7%, respectively. While PCR of FVU detected the greatest number of C. trachomatis infections (sensitivity, 96.1%), for some PCR-positive FVU specimens the results could not be confirmed (specificity, 99.6%). PCR and LCR were more sensitive than culture (sensitivities, 92 and 93% versus 79% for culture) in the diagnosis of genital C. trachomatis infection. In conclusion, both tests can be recommended for use in the clinical laboratory and for the screening of asymptomatic C. trachomatis infections. Chlamydia trachomatis is one of the most common causes of treatable sexually transmitted diseases (28). Serious sequelae, including pelvic inflammatory disease, tubal factor infertility, ectopic pregnancy, chronic abdominal pain, and reactive arthritis are associated with C. trachomatis infection (4, 14). Nonspecific clinical signs and symptoms of C. trachomatis infection and the frequent occurrence of asymptomatic infections render the clinical diagnosis of C. trachomatis infections difficult (24). Since asymptomatic individuals serve as a reservoir of infection and since complications also occur after silent infection, detection of infected individuals is a major challenge to the preventive health care system. With advances in DNA technology, laboratory methods for the amplification and detection of the multicopy plasmid DNA present in all C. trachomatis serovars have been introduced for the diagnosis of C. trachomatis infection (19). Theoretically, this approach offers high sensitivity (multicopy target) and high specificity (the target is present only in C. trachomatis). The PCR or ligase chain reaction (LCR) technology is demanding with respect to laboratory facilities and equipment, but standardized easy-to-use kits are available. Furthermore, partially automated assays (e.g., the LCx Chlamydia trachomatis assay; Abbott Laboratories, North Chicago, Ill.) and fully automated assays (Cobas Amplicor Chlamydia trachomatis [CT/NG] test; Roche Diagnostic Systems Inc., Branchburg, N.J.) have been developed and are already available for routine use. Assays * Corresponding author. Mailing address: Haartman Institute, Department of Virology, P.O. Box 21, FIN University of Helsinki, Helsinki, Finland. Phone: Fax: Mirja.Puolakkainen@Helsinki.fi. based on PCR (Cobas Amplicor) and LCR (LCx) tests have been applied in the detection of C. trachomatis infection worldwide. Testing of first-void urine (FVU) specimens has been a major breakthrough in the detection of chlamydial infection in both symptomatic and asymptomatic males and females (1 3, 5, 11, 12, 18, 20 22, 26). Both PCR and LCR tests have proven to be superior in the diagnosis of C. trachomatis infection when compared to the previously used methods in terms of both sensitivity and specificity. However, reports of few studies that have compared the two most widely used amplification methods have been published (6, 17). Our objective was to compare the performance of an automated PCR test (Roche Cobas Amplicor Chlamydia trachomatis [CT/NG] Test) and an LCR test (Abbott LCx Chlamydia trachomatis assay) with endocervical and urethral swab specimen culture as a reference test. We also wanted to assess the rate of inhibition of the amplification reaction in our material using the PCR test, which includes an internal control (IC). The effect of freezing on the performance of PCR and LCR testing of urine was also studied. In addition, the clinical utility of testing urine samples instead of swab specimens was studied. MATERIALS AND METHODS Patients. From May 1996 through October 1996, a total of 1,030 patients were recruited into the study. Informed consent was obtained from all patients, and a questionnaire regarding symptoms, sexual behavior, and contraception was completed. Altogether, 912 patients attending a sexually transmitted disease (STD) clinic and 118 females attending a clinic for adolescents in Helsinki were included in the study. Both symptomatic and asymptomatic patients were included. None of the patients had received antibiotic treatment 1 week prior to the visit. Specimen collection and aliquoting. One endocervical swab specimen obtained from each woman or a urethral swab specimen obtained from each man was placed into C. trachomatis transport medium (2SP). Another endocervical or 1489
2 1490 PUOLAKKAINEN ET AL. J. CLIN. MICROBIOL. urethral swab (LCx STD swab; Abbott) specimen was placed into an LCx STD swab Transport Tube. The order of collection of the swabs was alternated weekly. FVU (10 to 50 ml) was collected after swabbing of the urethra for males and before swabbing of the endocervix for females and was transferred to a 15-ml polypropylene tube. The 2SP specimens were stored at 4 C, transported to the laboratory, and processed within 24 h; the specimens collected on Friday afternoons, however, were stored at 4 C over the weekend and were processed on the following Monday morning. This is a standard practice in our laboratory. The specimens in 2SP were aliquoted for culture, PCR, and direct fluorescent-antibody (DFA) testing. The FVU specimens were stored at 4 C and transported to the laboratory within 24 h (except the specimens collected on Friday afternoons, which were stored at 4 C over the weekend and transported on the following Monday morning) and were then aliquoted to be tested fresh (stored at 4 C for up to 4 [LCR] or 7 [PCR] days) and frozen ( 20 C) and to be used in discrepant analyses. Specimen testing. Culture for C. trachomatis was performed with an aliquot from the 2SP medium. PCR was performed with one aliquot of fresh urine and one aliquot of frozen urine, as well as with an aliquot of 2SP medium. LCR was performed with one aliquot of fresh urine, one aliquot of frozen urine, and an aliquot of the LCx swab transport medium. Culture of C. trachomatis. Specimens in 2SP medium were vortexed vigorously. Aliquots of 250 l were inoculated onto McCoy cell monolayers growing on glass coverslips in 24-well plates. After the plates were centrifuged at 3,400 g for1h at 32 C, the inoculum was removed and was replaced with culture medium (BHK-21 with 10% fetal calf serum, 2 mm glutamine, gentamicin, vancomycin, and nystatin) containing 0.5 g of cycloheximide per ml. The cultures were incubated at 37 C in a 5% CO 2 atmosphere. After 48 h, the cultures were fixed with methanol, stained with fluorescein isothiocyanate-labeled MikroTrak Chlamydia trachomatis Culture Confirmation Reagent (Syva, Palo Alto, Calif.), and examined microscopically for the presence of chlamydial inclusions. DFA testing. An aliquot of 2SP medium (100 l) was centrifuged at 10,500 g for 10 min, and the pellet was suspended in phosphate-buffered saline (PBS) and smeared on a glass slide. The slide was fixed in methanol at 20 C for 10 min and stained with fluorescein isothiocyanate-labeled MikroTrak Chlamydia trachomatis Direct Specimen Reagent (Syva) and examined microscopically for the presence of C. trachomatis elementary bodies (EBs). Cobas Amplicor CT/NG test. The Cobas Amplicor CT/NG PCR test was performed according to the manufacturer s instructions. Fresh urine samples were vortexed vigorously. Frozen urine samples were completely thawed and were vortexed vigorously. A 500- l aliquot of urine was transferred to a polypropylene tube containing 500 l of CT/NG Urine Wash Buffer, and the contents were mixed well by vortexing. The tubes were incubated at 37 C for 15 min and centrifuged at 12,500 g for 5 min. The supernatant was discarded and the remnants of the supernatant in each tube were blotted on a separate sheet of absorbent paper. A total of 250 l of CT/NG Lysis Buffer was added to each tube, and the contents were mixed well by vortexing. After incubation for 15 min at room temperature, 250 l of CT/NG Specimen Diluent was added to each tube and the contents were mixed by vortexing. The tubes were centrifuged at 12,500 g for 10 min, and a 50- l aliquot of each supernatant was used for testing. The endocervical or urethral swab specimens collected in 2SP medium were processed as follows: 100 l of CT/NG Lysis Buffer was mixed with 100 l ofthe 2SP medium and the mixture was incubated at room temperature for 10 min. A total of 200 l of CT/NG Specimen Diluent was added the each tube, and the tubes were incubated at room temperature for 10 min. Aerosol-barrier pipette tips were used throughout the procedure. Of the processed specimens, an aliquot of 50 l was transferred to A-tubes containing the Working Master Mix, and the tubes were placed into the thermal cycler segments of the Cobas Amplicor. Amplification and detection of C. trachomatis and IC DNA were automatically performed by the Cobas Amplicor system. Results were expressed as A 660 and were regarded as positive (C. trachomatis A 660, 0.8), as negative (C. trachomatis A 660, 0.2; IC A 660, 0.2), or in a gray zone (C. trachomatis A 660, 0.2 but 0.8). For inhibitory specimens the A 660 of the IC was 0.2 and that of C. trachomatis was 0.2. For specimens containing inhibitory substances, another aliquot was tested at full strength and following 1:10 dilution in CT/NG Specimen Diluent. Abbott LCx Chlamydia trachomatis assay. The LCR test was performed according to the manufacturer s instructions. A 1-ml aliquot of the FVU was centrifuged at 13,000 g for 15 min and the supernatant was discarded. The pellet was resuspended in 1 ml of LCx Urine Specimen Resuspension Buffer. The treated FVU samples and swab specimens in the transport tubes were heated at 97 C for 15 min. For amplification of Chlamydia by LCx, 100 l of the treated specimens was used. An LCx Analyzer (microparticle enzyme immunoassay) was used to detect the amplicons. The LCx Analyzer calculated the cutoff value (0.45 mean of LCx Chlamydia Calibrator Values), and specimens with an assay value equal to or greater than the cutoff value were considered positive. Discrepant analysis. The results for any set of patient specimens without unanimous results for both specimen types in all tests were considered discrepant. The specimens were retested as follows. To check for the presence of nonviable C. trachomatis EBs in culture-negative samples with discrepant results, the DFA assay was performed with the 2SP medium sediment. If either the FVU or the swab tested in the LCx assay had discrepant results, the specimen was retested both undiluted and following 1:10 dilution in LCx Urine Specimen Buffer. The LCx assay was repeated with the processed swab specimen. One of the frozen aliquots of urine was also processed and tested. Retesting of the specimens with discrepant results by the Cobas Amplicor CT/NG test and confirmatory PCR for the major outer membrane protein (MOMP) were done blindly at Roche Diagnostic Systems Inc., Basel, Switzerland. Samples (aliquots of unprocessed 2SP and frozen urine) were sent there coded, and the set included known positive and known negative samples. However, the results obtained by retesting were not used to create an expanded reference standard to avoid bias in the analyses (10). Statistical analysis. The diagnostic consistency of different tests for different specimen types was calculated as described by Cohen (7). The diagnostic accuracy of different tests for different specimen types was calculated according to current guidelines for evaluation of C. trachomatis diagnostic tests (9). RESULTS Of the 1,030 patients, 15 patients had an incomplete set of specimens and were excluded, leaving 1,015 patients for evaluation. By culture, C. trachomatis infection was detected in 7.4% (42 of 565) of the males and 4.2% (19 of 449) of the females (one culture could not be evaluated due to toxicity). Higher prevalence was obtained by testing swabs or FVUs by PCR (males, 8.8 to 9.2%; females, 6.0 to 6.3%) or LCR (males, 8.0 to 8.1%; females, 4.9 to 5.6%) (Table 1). It was noteworthy that the gender-specific difference seen by culture was much smaller than that seen by PCR or LCR. The results of all five tests were identical for 945 (93%) of the 1,015 patients. All of the available test results were identical for an additional 39 patients. Altogether, all available test results were in agreement for 984 (97%) of the 1,015 patients. The patient group with an incomplete set of results includes 1 patient with a toxic chlamydial culture, 10 patients whose specimens were inhibitory by using an IC in the PCR, 3 patients whose specimens did not give a result in the LCR (repeatedly error code 166), and 25 patients for whom LCR results were not available. Statistical testing of the diagnostic consistency of the PCR and LCR methods gave kappa coefficients of 0.93 for swab specimens and 0.95 for FVU specimens. In order to calculate test performance, a patient was considered to have a proven C. trachomatis infection if the culture result was positive (61 patients) or if both PCR and LCR performed with either specimen type gave a positive result (16 patients). Thus, 77 patients had true-positive results and 938 patients had true-negative results. Culture detected 79.2% of the positive patients. The sensitivities of testing of FVU by PCR and LCR were 96.1 and 93.3%, respectively (Table 1). The specificities of all the tests used were high (100% for culture and LCR and greater than 99% for PCR). The discrepant results for 31 patients are presented in Table 2. For 10 patients (three females and seven males), C. trachomatis culture failed to detect an infection, although the same swab specimen was positive by PCR and another swab specimen was positive by LCR (eight patients; results of LCR with swab specimens were not available for two patients). Also, testing of FVU by both PCR and LCR gave a positive result for eight patients, but the result remained negative for two patients. When an aliquot of the 2SP was studied by the DFA assay, six of the eight samples tested showed typical C. trachomatis EBs. Discrepant analysis detected C. trachomatis plasmid DNA or MOMP DNA in specimens from all these patients. Also, culture failed for five patients (all females), for whom only PCR and LCR testing of FVU gave a positive result. No C. trachomatis MOMP DNA could be found in aliquots of 2SP or processed LCx swab specimens, whereas FVU aliquots from two of the four patients tested were also positive for C. trachomatis MOMP DNA. Testing of FVU by PCR failed to detect C. trachomatis in one male patient, and testing of FVU by LCR failed to detect
3 VOL. 36, 1998 PCR AND LCR IN DETECTION OF C. TRACHOMATIS INFECTION 1491 Patient sex and test (specimen) TABLE 1. Diagnostic performance of different samples in detection of urogenital C. trachomatis infection No. of specimens positive/ no. of specimens tested (%) Sensitivity (%) Specificity (%) PPV (%) a NPV (%) b Women Culture (swab c ) 19/449 (4.2) 67.9 (19/28) d 100 (421/421) 100 (19/19) 97.9 (421/430) PCR (swab) 27/447 (6.0) 78.6 (22/28) 98.8 (414/419) 81.5 (22/27) 98.6 (414/420) LCR (swab) 22/448 (4.9) 81.5 (22/27) 100 (421/421) 100 (22/22) 98.8 (421/426) PCR (FVU) 28/442 (6.3) 96.4 (27/28) 99.8 (413/414) 96.4 (27/28) 99.8 (413/414) LCR (FVU) 25/443 (5.6) 92.6 (25/27) 100 (406/406) 100 (25/25) 99.5 (406/408) Men Culture (swab) 42/565 (7.4) 85.7 (42/49) 100 (516/516) 100 (42/42) 98.7 (516/523) PCR (swab) 52/565 (9.2) 100 (49/49) 99.4 (513/516) 94.2 (49/52) 100 (513/513) LCR (swab) 45/557 (8.1) 100 (45/45) 100 (512/512) 100 (45/45) 100 (512/512) PCR (FVU) 50/565 (8.8) 95.9 (47/49) 99.4 (513/516) 94.0 (47/50) 99.6 (513/515) LCR (FVU) 45/560 (8.0) 93.8 (45/48) 100 (512/512) 100 (45/45) 99.4 (512/515) Combined Culture (swab) 61/1,014 (6.0) 79.2 (61/77) 100 (937/937) 100 (61/61) 98.3 (937/953) PCR (swab) 79/1,012 (7.8) 92.2 (71/77) 99.1 (927/935) 89.9 (71/79) 99.4 (927/933) LCR (swab) 67/1,005 (6.7) 93.1 (67/72) 100 (933/933) 100 (67/67) 99.5 (933/938) PCR (FVU) 78/1,007 (7.7) 96.1 (74/77) 99.6 (926/930) 94.9 (74/78) 99.7 (926/929) LCR (FVU) 70/993 (7.0) 93.3 (70/75) 100 (918/918) 100 (70/70) 99.5 (918/923) a PPV, positive predictive value. b NPV, negative predictive value. c Swab, endocervical swab from females and urethral swab from males. d Values in parentheses are numbers used to calculate sensitivity, specificity, PPV, and NPV (9). C. trachomatis in one female and two males. However, discrepant analysis revealed C. trachomatis DNA in another aliquot of FVU from these three patients. Eleven patients had positive results only by PCR. FVU gave a positive signal for four patients and 2SP gave a positive signal for eight patients (both the swab and the urine were positive or one patient). Two of these 11 patients were confirmed to be positive by PCR for MOMP and plasmid-based PCR with another aliquot of FVU, 2SP, or a processed LCx swab specimen. These patients were not counted as true positives when calculating the performance of the tests, since an expanded gold standard was not created. However, 9 of these 11 patients most likely initially had false-positive PCR results because they remained negative when retested by PCR for No. of patients Culture with swab PCR with swab TABLE 2. Analysis of discrepant test results by culture, PCR, and LCR a Result LCR with swab PCR with FVU LCR with FVU MOMP and plasmid-based PCR. For one female, only tests performed with the 2SP medium (culture, PCR, and the DFA assay) remained negative, although PCR of FVU and LCR of swabs as well as LCR of FVU gave positive results, suggesting technical failure in swabbing. Detection of the IC by PCR. Specimens from 10 (1%) patients were found to be inhibitory when tested for the IC in the Cobas Amplicor Chlamydia trachomatis (CT/NG) Test. These were eight urine samples and three endocervical swab specimens (from one female, both the FVU and the swab specimen turned out to be inhibitory). All samples were from females (mean age, 34 years; age range, 20 to 51 years). Six were symptomatic and four were asymptomatic. One used birth control pills, and none was taking antibiotics. In addition to these No. of M/ no. of F Comment 6 5/1 FN by culture b 2 NA 1/1 FN by culture 2 1/1 FN by culture; no C. trachomatis DNA in FVU 5 0/5 No C. trachomatis in swabs 3 2/1 FN by LCR with FVU 1 NA 1/0 FN by PCR with FVU 3 2/1 FP by PCR with FVU c 7 0/7 FP by PCR with swab (n 6) d ;TPbyPCR with swab (n 1) e 1 1/0 TP by PCR e 1 0/1 Obvious swabbing failure a Abbreviations: FN, false negative; FP, false positive; TP, true positive; NA, not available; M, male; F, female. b The DFA assay showed C. trachomatis particles in the culture specimen; both the culture specimen and FVU contained MOMP DNA by PCR. c The initial positive results by PCR of FVU could not be confirmed by any other test, and also reanalysis of another (frozen) aliquot of FVU remained negative by PCR for plasmid DNA and PCR for MOMP DNA. d The initial positive results by PCR with swabs could not be confirmed by any other test. e C. trachomatis MOMP DNA was found in the culture specimen and in FVU by PCR.
4 1492 PUOLAKKAINEN ET AL. J. CLIN. MICROBIOL. 11 specimens, the amplification of the IC was negative for another 11 specimens that were positive for C. trachomatis. Testing of frozen FVU. Aliquots of FVU were stored at 20 C for 2 to 6 months before retesting by PCR and LCR. Fewer positive results were obtained by both PCR and LCR when frozen aliquots of FVU were thawed and analyzed. Ten of the 78 initially PCR-positive FVU specimens became negative. Six of these were from patients with other positive markers for C. trachomatis infection, and four were most likely initially false positive. Four of the 10 aliquots of FVU were also initially LCR positive and all also became negative by LCR. Seven of the 70 initially LCR-positive FVU specimens became negative by LCR. Six of these seven were from patients with true C. trachomatis infection, and one was most likely an initially false-positive result. Four of the seven aliquots of FVU were also initially PCR positive and all also became negative by PCR. DISCUSSION Most urogenital C. trachomatis infections are initially asymptomatic but may subsequently cause considerable long-term morbidity. Consequently, accurate diagnosis of C. trachomatis infection requires the use of specific laboratory techniques. Performance of these methods varies considerably. Culture was earlier considered the gold standard, but PCR and LCR studies suggests that the sensitivity of the culture even in expert laboratories is as low as 75 to 85% (5, 21). It is universally accepted that culture can no longer serve as a reference method in the evaluation of diagnostic tests for C. trachomatis. Recently introduced PCR and LCR techniques have been shown to be very sensitive in the diagnosis of chlamydial infection of the male urethra and in detecting chlamydial DNA in male urine specimens. Lower sensitivity has usually been observed when female specimens have been tested, possibly due to the more frequent occurrence of inhibitors in the specimens. For the first time, we compared the diagnostic performance of commercially available PCR and LCR with both swabs and FVU using cell culture as the reference. In earlier studies evaluating PCR and LCR, FVU had been tested by the amplification methods and swabs had been tested by culture (17) or by culture and the DFA assay (6). In our hands, testing of FVU from females and urethral swabs from males by nucleic acid amplification methods detected most C. trachomatis-positive patients. Culture was less sensitive for female endocervical swabs than for male urethral swabs (67.9 versus 85.7%). Thus, culture missed every third infected female and 14% of the infected males. The site of infection might, however, well explain why swab PCR and LCR failed to detect C. trachomatis infection in six patients, because all these women had negative cervical specimen culture results and chlamydial DNA was found in the FVU only. This study showed that PCR and LCR showed excellent consistency by kappa coefficients and performed better than culture when compared to our standard (positive culture result or positive PCR and LCR results with either specimen type). Use of discrepant analysis is one attempt to improve the performance characteristics of the reference method. Discrepant analysis aims to identify by an alternative (confirmatory) method true-positive specimens originally missed by the reference method. However, if only samples with discrepant results are tested by confirmatory tests, which is usually the case, a bias is introduced (10). The selective testing includes only specimens initially giving discrepant results and could theoretically favor the performance of the tests being evaluated. In our material, the criteria for proven infection were culture positivity or both PCR and LCR positivity. Discrepant analysis was done, but the results were used only to clarify the initial results. An expanded reference standard was not created, although this was recommended recently by the STD Diagnostic Initiative (9). Our retesting showed that 60% of the swab specimens that were obviously culture failures did contain C. trachomatis EBs when the specimens were analyzed by DFA staining. This is as expected, since culture and DFA assay are considered less sensitive than PCR. Clinical specimens are known to contain several factors that inhibit DNA polymerase. Roche has developed a system that permits the identification of such polymerase reaction-inhibiting factors: detection of amplification of an IC in included in the Cobas Amplicor test, thus ensuring the integrity of the result. In our material, the occurrence of such inhibitors was low (less than 1%). Others have noted higher inhibition rates detectable with the IC system with clinical specimens (16) or spiked clinical specimens (27). It is possible that in this study obvious false-negative LCR results were due to the presence of inhibitors of the LCR, but this could not be confirmed in our study, because the LCx does not incorporate an internal control. Our earlier experience with the PCR, LCR, and transcription-mediated amplification (TMA) techniques in routine clinical microbiology laboratory use suggests that some specimens contain factors that inhibit the amplification reactions, but the factors are not identical for different techniques. Specificity is another concern with the DNA amplification techniques. Theoretically, the tests are highly specific, but because the potential of the amplification reaction is enormous, even a slight contamination can result in erroneous results. In published studies, PCR is usually found to be more sensitive and LCR is found to be more specific when compared to the sensitivity and specificity of a created standard (6, 17). This was also the case in our study when FVU specimens were analyzed: The sensitivities of PCR and LCR were 96.1 versus 93.3%, respectively, and the specificities of the tests were 99.6 versus 100%, respectively. To increase the specificities of the amplification techniques, retesting of the initially positive specimens or confirmation of the results by another amplification method can be done. However, because freezing and thawing of the specimen can have an effect on test performance, the results may not be comparable. Freezing and thawing can eliminate inhibitory factors (25), but as our results suggest, the DNA in the specimens can also be degraded. The most attractive aspects of DNA amplification methods are their excellent sensitivities and good performance with FVU samples. In our study, 96 and 93% of the infections could be detected by testing FVU by PCR or LCR, respectively, when the results for symptomatic and asymptomatic patients were analyzed together. In the detection of both symptomatic and asymptomatic infections, testing of FVU by PCR or LCR is thus a preferred alternative to testing of swab specimens for both females and males. We have shown earlier that screening for chlamydial infections by the PCR test with FVU is costbeneficial in a low-prevalence population if the prevalence of infection exceeds 3.9% (15). Because recent studies suggest that C. trachomatis infection is also a risk factor for adverse pregnancy outcomes other than ectopic pregnancy (8) and is possibly also a risk factor for the development of cervical neoplasia (13), the cost-effectiveness of screening of the sexually active population by DNA amplification methods needs to be reevaluated. ACKNOWLEDGMENTS We thank Marja Pietilä, Maarit Ohranen, and Maaria Vainio for skillful technical assistance. The skillful personnel of the STD clinic,
5 VOL. 36, 1998 PCR AND LCR IN DETECTION OF C. TRACHOMATIS INFECTION 1493 Helsinki University Central Hospital, as well as Maritta Slotte and Katriina Bildjuschkin, Sexual Health Clinic of Väestöliitto, Counseling and Services for Adolescents, the Family Federation of Finland, Helsinki, are gratefully acknowledged for collecting all the samples. This study was supported by a grant from the Helsinki University Central Hospital Research Funds and by Roche Diagnostic Systems Inc., Basel, Switzerland. REFERENCES 1. Ånestad, G., B. P. Berdal, O. Scheel, R. Mundal, O. Odinsen, K. Skaug, O. S. Khalil, P. Plier, and H. Lee Screening urine samples by leukocyte esterase test and ligase chain reaction for chlamydial infections among asymptomatic men. J. Clin. Microbiol. 33: Bauwens, J. E., A. M. Clark, M. J. Loeffelholz, S. A. Herman, and W. E. Stamm Diagnosis of Chlamydia trachomatis urethritis in men by polymerase chain reaction assay of first-catch urine. J. Clin. Microbiol. 31: Bauwens, J. E., A. M. Clark, and W. E. Stamm Diagnosis of Chlamydia trachomatis endocervical infections by a commercial polymerase chain reaction assay. J. Clin. Microbiol. 31: Cates, W., and J. E. Wasserheit Genital chlamydial infections: epidemiology and reproductive sequelae. Am. J. Obstet. Gynecol. 164: Chernesky, M. A., D. Jang, H. Lee, J. D. Burczak, H. Hu, J. Sellors, S. J. Tomazic-Allen, and J. B. Mahony Diagnosis of Chlamydia trachomatis infections in men and women by testing first-void urine by ligase chain reaction. J. Clin. Microbiol. 32: Chernesky, M., S. Chong, D. Jang, K. Luinstra, J. Sellors, and J. B. Mahony Ability of commercial ligase chain reaction and PCR assays to diagnose Chlamydia trachomatis infections in men by testing first-void urine. J. Clin. Microbiol. 35: Cohen, J A coefficient of agreement for nominal scales. Educ. Psychol. 20: Gencay, M., M. Puolakkainen, T. Wahlström, P. Ämmälä, L. Mannonen, A. Vaheri, and M. L. Koskiniemi Chlamydia trachomatis detected in human placenta. J. Clin. Pathol. 50: Global Access to STD Diagnostics Guidelines for evaluating Chlamydia trachomatis Diagnostic Tests, p STD Initiative Program for Appropriate Technology in Health, vol. 4. Program for Appropriate Technology in Health (PATH), Seattle, Wash. 10. Hadgu, A The discrepancy in discrepant analysis. Lancet 348: Jaschek, G., C. A. Gaydos, L. E. Welsh, and T. C. Quinn Direct detection of Chlamydia trachomatis in urine specimens from symptomatic and asymptomatic men by using a rapid polymerase chain reaction assay. J. Clin. Microbiol. 31: Lee, H., M. A. Chernesky, J. Schachter, J. D. Burczak, W. W. Andrews, S. Muldoon, G. Leckie, and W. E. Stamm Diagnosis of Chlamydia trachomatis geniotourinary infection in women by ligase chain reaction assay of urine. Lancet 345: Lehtinen, M., J. Dillner, T. Luostarinen, A. Aromaa, M. H. Hibma, R. Kirnbauer, A. Miettinen, J. Paavonen, J. T. Schiller, and M. Hakama Nested case-control study of the role of human papillomavirus type 16 and Chlamydia trachomatis in cervical carcinoma: nested case-control study. Br. Med. J. 312: Paavonen, J Chlamydia trachomatis a major threat to reproduction. Eur. J. Obstet. Gynecol. Reprod. Biol. 49: Paavonen, J., M. Puolakkainen, M. Paukku, and H. Sintonen. Cost-benefit analysis of universal first void urine Chlamydia trachomatis screening program. Obstet. Gynecol., in press. 16. Pasternack, R., P. Vuorinen, A. Kuukankorpi, T. Pitkäjärvi, and A. Miettinen Detection of Chlamydia trachomatis infections in women by Amplicor PCR: comparison of diagnostic performance with urine and cervical specimens. J. Clin. Microbiol. 34: Pasternack, R., P. Vuorinen, T. Pitkäjärvi, M. Koskela, and A. Miettinen Comparison of manual amplicor PCR, Cobas Amplicor PCR, and LCx assays for detection of Chlamydia trachomatis infection in women by using urine specimens. J. Clin. Microbiol. 35: Paukku, M., M. Puolakkainen, D. Apter, S. Hirvonen, and J. Paavonen First-void urine testing for Chlamydia trachomatis by polymerase chain reaction in women in a low prevalence population. Sex. Transm. Dis. 24: Quinn, T Advances in the molecular diagnosis of Chlamydia trachomatis, p In A. Stary (ed.), Proceedings of the Third Meeting of the European Society for Chlamydia Research. Societa Editrice Esculapio, Bologna, Italy. 20. Quinn, T. C., L. Welsh, A. Lentz, K. Crotchfelt, J. Zenilman, J. Newhall, and C. Gaydos Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine from women and men attending sexually transmitted disease clinic. J. Clin. Microbiol. 34: Ridgway, G. L., G. Mumtaz, A. J. Robinson, M. Franschini, C. Carder, J. Burczak, and H. Lee Comparison of the ligase chain reaction with cell culture for the diagnosis of Chlamydia trachomatis infection in women. J. Clin. Pathol. 49: Schachter, J., J. Moncada, R. Whidden, H. Swah, G. Bolan, J. D. Burczak, and H. Lee Noninvasive tests for diagnosis of Chlamydia trachomatis infection: application of ligase chain reaction to first-catch urine specimens of women. J. Infect. Dis. 172: Schachter, J Evolution of diagnostic tests for Chlamydia trachomatis infections, p In A. Stary (ed.), Proceedings of the Third Meeting of the European Society for Chlamydia Research. Societa Editrice Esculapio, Bologna, Italy. 24. Stamm, W. E., L. A. Koutsky, J. K. Benedetti, J. L. Jourden, R. C. Brunham, and K. K. Holmes Chlamydia trachomatis urethral infections in men: prevalence, risk factors, and clinical manifestations. Ann. Intern. Med. 100: Stary, A., B. Choueiri, I. Hörting-Müller, P. Halisch, and L. Teodorowich Detection of Chlamydia trachomatis in urethral and urine samples from symptomatic and asymptomatic male patients by the polymerase chain reaction. Eur. J. Clin. Microbiol. Infect. Dis. 15: Toye, B., R. W. Peeling, P. Jessamine, P. Claman, and I. Gemmill Diagnosis of Chlamydia trachomatis infections in asymptomatic men and women by PCR assay. J. Clin. Microbiol. 34: Verkooyen, R. P., A. Luijendijk, W. M. Huisman, W. H. F. Goessens, J. A. J. W. Kluytmans, J. H. van Rijsoort-Vos, and H. A. Verbrugh Detection of PCR inhibitors in cervical specimens by using the AMPLICOR Chlamydia trachomatis Assay. J. Clin. Microbiol. 34: World Health Organization An overview of selected curable sexually transmitted diseases. Global Programme on AIDS, World Health Organization, Geneva, Switzerland.
A Comparison of Ligase Chain Reaction to
Infectious Diseases in Obstetrics and Gynecology 6:57-60 (I 998) (C) 1998 Wiley-Liss, Inc. A Comparison of Ligase Chain Reaction to Polymerase Chain Reaction in the Detection of C.hlamydia trachomatis
More informationJOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1998, p Vol. 36, No. 11. Copyright 1998, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1998, p. 3122 3126 Vol. 36, No. 11 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology. All Rights Reserved. Urine Specimens from Pregnant and
More informationEvaluation of the Vidas Chlamydia Test To Detect and Verify Chlamydia trachomatis in Urogenital Specimens
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 1997, p. 2102 2106 Vol. 35, No. 8 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Evaluation of the Vidas Chlamydia Test To Detect and Verify
More informationComparison of Three Nucleic Acid Amplification Tests for Detection of Chlamydia trachomatis in Urine Specimens
JOURNAL OF CLINICAL MICROBIOLOGY, July 2004, p. 3041 3045 Vol. 42, No. 7 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.7.3041 3045.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationEvaluation of Nucleic Acid Amplification Tests as Reference Tests for Chlamydia trachomatis Infections in Asymptomatic Men
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2000, p. 4382 4386 Vol. 38, No. 12 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Evaluation of Nucleic Acid Amplification
More informationMailed, Home-Obtained Urine Specimens: a Reliable Screening Approach for Detecting Asymptomatic Chlamydia trachomatis Infections
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 1999, p. 976 980 Vol. 37, No. 4 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Mailed, Home-Obtained Urine Specimens:
More informationDiagnosis by AMPLICOR PCR of Chlamydia trachomatis Infection in Urine Samples from Women and Men Attending Sexually Transmitted Disease Clinics
JOURNAL OF CLINICAL MICROBIOLOGY, June 1996, p. 1401 1406 Vol. 34, No. 6 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Diagnosis by AMPLICOR PCR of Chlamydia trachomatis Infection
More informationDiagnosis of Chlamydia trachomatis Infections in Asymptomatic Men and Women by PCR Assay
JOURNAL OF CLINICAL MICROBIOLOGY, June 1996, p. 1396 1400 Vol. 34, No. 6 0095-1137/96/$04.00 0 Copyright 1996, American Society for Microbiology Diagnosis of Chlamydia trachomatis Infections in Asymptomatic
More informationLowering the cut off value of an automated chlamydia enzyme immunoassay and confirmation
J Clin Pathol 1997;50:681-685 Department of Medical Microbiology and Genitourinary Medicine, University of Liverpool, Liverpool, UK C Y W Tong Department of Virology, Royal Liverpool University Hospital,
More informationMasatoshi Tanaka, Hiroshi Nakayama, Kazuyuki Sagiyama, Masashi Haraoka, Hiroshi Yoshida, Toshikatsu Hagiwara, Kohei Akazawa, Seiji Naito
350 J Clin Pathol 2000;53:350 354 Papers Urology, Faculty of Medicine, Kyushu University, 3 1 1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan M Tanaka M Haraoka S Naito Medical Informatics, Faculty of
More informationEvaluation of Bias in Diagnostic-Test Sensitivity and Specificity Estimates Computed by Discrepant Analysis
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 1998, p. 375 381 Vol. 36, No. 2 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology Evaluation of Bias in Diagnostic-Test Sensitivity and Specificity
More informationReceived 13 November 1997/Returned for modification 27 January 1998/Accepted 16 February 1998
JOURNAL OF CLINICAL MICROBIOLOGY, May 1998, p. 1300 1304 Vol. 36, No. 5 0095-1137/98/$04.00 0 Copyright 1998, American Society for Microbiology Use of Ligase Chain Reaction with Urine versus Cervical Culture
More informationReceived 26 November 2003/Returned for modification 6 January 2004/Accepted 6 April 2004
JOURNAL OF CLINICAL MICROBIOLOGY, July 2004, p. 3089 3093 Vol. 42, No. 7 0095-1137/04/$08.00 0 DOI: 10.1128/JCM.42.7.3089 3093.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationReceived 21 March 2005/Returned for modification 25 April 2005/Accepted 9 June 2005
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2005, p. 4684 4690 Vol. 43, No. 9 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.9.4684 4690.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationReceived 8 September 2005/Returned for modification 12 October 2005/Accepted 9 November 2005
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2006, p. 400 405 Vol. 44, No. 2 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.2.400 405.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved. High
More informationEvaluation of CDC-Recommended Approaches for Confirmatory Testing of Positive Neisseria gonorrhoeae Nucleic Acid Amplification Test Results
JOURNAL OF CLINICAL MICROBIOLOGY, May 2008, p. 1614 1619 Vol. 46, No. 5 0095-1137/08/$08.00 0 doi:10.1128/jcm.02301-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Evaluation
More informationTechnical Bulletin No. 98b
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 98b Chlamydia trachomatis and Neisseria gonorrhoeae Dual Target PCR Assay UPDATED Specimen Requirements October 13, 2016 Contact: Susan
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2001, p. 829 835 Vol. 39, No. 3 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.3.829 835.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved. Comparison
More informationJOURNAL OF CLINICAL MICROBIOLOGY, July 1999, p Vol. 37, No. 7. Copyright 1999, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, July 1999, p. 2223 2229 Vol. 37, No. 7 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Comparison of the PACE 2 Assay, Two
More informationA School-based Chlamydia Control Program Using DNA Amplification Technology
A School-based Chlamydia Control Program Using DNA Amplification Technology Deborah A. Cohen, MD, MPH* ; Malanda Nsuami, MD, MPH*; Roger Bedimo Etame, MD, MSc*; Susanne Tropez-Sims, MD* ; Sue Abdalian,
More informationReceived 16 December 2005/Returned for modification 6 February 2006/Accepted 6 May 2006
JOURNAL OF CLINICAL MICROBIOLOGY, July 2006, p. 2512 2517 Vol. 44, No. 7 0095-1137/06/$08.00 0 doi:10.1128/jcm.02620-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. Detection
More informationCorrect samples for diagnostic tests in sexually transmitted diseases: which sample for which test? 1
FEMS Immunology and Medical Microbiology 24 (1999) 455^459 Correct samples for diagnostic tests in sexually transmitted diseases: which sample for which test? 1 Angelika Stary * Outpatient's Center for
More informationImmunodiagnosis of Sexually Transmitted Disease
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 58 (1985), 443-452 Immunodiagnosis of Sexually Transmitted Disease JULIUS SCHACHTER, Ph.D. Department oflaboratory Medicine, University of California, San Francisco,
More informationEffect of Endocervical Specimen Adequacy for Detection of ACCEPTED. Wyoming Public Health Laboratory, 517 Hathaway Bldg., 2300 Capitol Ave.
JCM Accepts, published online ahead of print on October 00 J. Clin. Microbiol. doi:./jcm.001-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationInfection with Chlamydia trachomatis is
In Women: A Comparison of Three Sets of Criteria By Jeanne M. Marrazzo, David Fine, Connie L. Celum, Susan DeLisle and H. Hunter Handsfield Selective screening has been associated with marked declines
More informationCost-benefit analysis of first-void urine Chlamydia trachomatis screening program Paavonen J, Puolakkainen M, Paukku M, Sintonen H
Cost-benefit analysis of first-void urine Chlamydia trachomatis screening program Paavonen J, Puolakkainen M, Paukku M, Sintonen H Record Status This is a critical abstract of an economic evaluation that
More informationControls for Chlamydia trachomatis and Neisseria gonorrhoea
Controls for Chlamydia trachomatis and Neisseria gonorrhoea Mark Manak, Ph.D., SeraCare Life Sciences Gaithersburg, MD USA SoGAT Clinical Diagnostic Meeting NIBSC, South Mimms, UK June 25, 2008 C. trachomatis
More informationControls for Chlamydia trachomatis and Neisseria gonorrhoea
Controls for Chlamydia trachomatis and Neisseria gonorrhoea Mark Manak, Ph.D., Phil Moen, Ph.D., Bharathi Anekella, Ph.D SeraCare Life Sciences Gaithersburg, MD USA SoGAT Clinical Diagnostic Meeting NIBSC,
More informationEvaluation of the microparticle enzyme immunoassay Abbott IMx Select Chlamydia and
498 Original article Department of Clinical Microbiology, Auckland Hospital, Auckland, New Zealand M K Brokenshire A H van Vonno C Wong Auckland Sexual Health Service, Auckland Hospital, Auckland, New
More informationEffect of Blind Passage and Multiple Sampling on Recovery of Chlamydia trachomatis from Urogenital Specimens
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1986, p. 1029-1033 0095-1137/86/121029-05$02.00/0 Copyright 1986, American Society for Microbiology Vol. 24, No. 6 Effect of Blind Passage and Multiple Sampling on
More informationOptimal collection of first-void urine for detection of Chlamydia. trachomatis infection in men ACCEPTED. Beng T. Goh, 4 Helen H.
JCM Accepts, published online ahead of print on 30 January 2008 J. Clin. Microbiol. doi:10.1128/jcm.02241-07 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationThe accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review
J. Med. Microbiol. Vol. 51 (2002), 1021 1031 # 2002 Society for General Microbiology ISSN 0022-2615 REVIEW ARTICLE The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review
More informationReceived 12 July 2004/Returned for modification 29 August 2004/Accepted 18 October 2004
JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2005, p. 577 584 Vol. 43, No. 2 0095-1137/05/$08.00 0 doi:10.1128/jcm.43.2.577 584.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved. Impact
More information2014 CDC GUIDELINES CHLAMYDIA & GONORRHEA DIAGNOSTICS. Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham
2014 CDC GUIDELINES CHLAMYDIA & GONORRHEA DIAGNOSTICS Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham DISCLOSURES Honorarium, Speaking Fees or Research Support Atlas Genetics BD Diagnostics
More informationAssessment of Chlamydia trachomatis infection in asymptomatic male partners of infertile couples
Journal of Medical Microbiology (2004), 53, 985 990 DOI 10.1099/jmm.0.45641-0 Assessment of Chlamydia trachomatis infection in asymptomatic male partners of infertile couples Farida Hamdad-Daoudi, 1 Jacques
More informationOriginal article. Office of Disease Prevention and Control, region 10 Chiang Mai, 2 Sanpatong Hospital, 3
Original article A retrospective study of relationship between white blood cell counts in cervical discharge and Chlamydial cervicitis among young adults: is the simple microscope an alternative method
More informationReceived 11 April 2003/Returned for modification 10 June 2003/Accepted 30 June 2003
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2003, p. 4395 4399 Vol. 41, No. 9 0095-1137/03/$08.00 0 DOI: 10.1128/JCM.41.9.4395 4399.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationThe value of urine samples from men with nongonococcal
124 Genitourin Med 1991;67:124-128 The value of urine samples from men with nongonococcal urethritis for the detection of Chlamydia trachomatis P E Hay, B J Thomas, C Gilchrist, H M Palmer, C B Gilroy,
More informationISPUB.COM. Chlamydia in female reproductive tract. D Pandey, J Shetty, M Pai, Pratapkumar INTRODUCTION BURDEN OF SUFFERING MICROBIOLOGICAL ASPECT
ISPUB.COM The Internet Journal of Infectious Diseases Volume 7 Number 1 Chlamydia in female reproductive tract D Pandey, J Shetty, M Pai, Pratapkumar Citation D Pandey, J Shetty, M Pai, Pratapkumar. Chlamydia
More informationChlamydia Trachomatis IgG ELISA Kit
Chlamydia Trachomatis IgG ELISA Kit Catalog Number KA0959 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationChlamydia trachomatis Load at Matched Anatomic Sites: Implications for Screening Strategies
JOURNAL OF CLINICAL MICROBIOLOGY, May 2007, p. 1395 1402 Vol. 45, No. 5 0095-1137/07/$08.00 0 doi:10.1128/jcm.00100-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Chlamydia
More informationJoyee A. George, Thyagarajan S. Panchatcharam*, Rajendran Paramasivam, Sowmya Balasubramanian, Venkatesan Chakrapani 1 and Ganapathy Murugan 1
Jpn. J. Infect. Dis., 56, 88-92, 2003 Original Article Evaluation of Diagnostic Efficacy of PCR Methods for Chlamydia trachomatis Infection in Genital and Urine Specimens of Symptomatic Men and Women in
More informationChlamydia Rapid Screen Test (RAP-2858) RUO in the USA. Revised 28 Jul 2006
INDICATION For the rapid detection of Chlamydia Trachomatis antigens in swab specimens. For in vitro diagnostic use only, except in the United States where it is intended for Research Use Only. SUMMARY
More informationEvaluation of a Modified Sanitary Napkin as a Sample Self-Collection Device for the Detection of Genital Chlamydial Infection in Women
JOURNAL OF CLINICAL MICROBIOLOGY, July. 2001, p. 2508 2512 Vol. 39, No. 7 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.7.2508 2512.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationChlamydia Trachomatis IgM ELISA Kit
Chlamydia Trachomatis IgM ELISA Kit Catalog Number KA0960 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle
More informationGenital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham
Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology
More informationLaboratory Methods for Detection of Chlamydia trachomatis: Survey of Laboratories in Washington State
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1997, p. 3210 3214 Vol. 35, No. 12 0095-1137/97/$04.00 0 Copyright 1997, American Society for Microbiology Laboratory Methods for Detection of Chlamydia trachomatis:
More informationCHLAMYDIA/GC AMPLIFIED RNA ASSAY
Lab Dept: Test Name: Microbiology/Virology CHLAMYDIA/GC AMPLIFIED RNA ASSAY General Information Lab Order Codes: CGRNA Synonyms: CPT Codes: Test Includes: Chlamydia trachomatis/neisseria gonorrhoeae by
More informationComparison of Gen-Probe DNA Probe Test and Culture for the Detection of Neisseria gonorrhoeae in Endocervical Specimens
JOURNAL OF CLINICAL MICROBIOLOGY, May 1991, p. 883-888 0095-1137/91/050883-06$02.00/0 Copyright X 1991, American Society for Microbiology Vol. 29, No. 5 Comparison of Gen-Probe DNA Probe Test and Culture
More informationDuration of Persistence of Gonococcal DNA Detected by Ligase Chain Reaction in Men and Women following Recommended Therapy for Uncomplicated Gonorrhea
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2002, p. 3596 3601 Vol. 40, No. 10 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.10.3596 3601.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationPerformance of Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification assays using low level controls
Performance of Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid amplification assays using low level controls 7 th International Symposium on Molecular Diagnostics, Graz, Austria May 2008 Phillip
More informationARTICLE. Is the Routine Pelvic Examination Needed With the Advent of Urine-Based Screening for Sexually Transmitted Diseases?
ARTICLE Is the Routine Pelvic Examination Needed With the Advent of Urine-Based Screening for Sexually Transmitted Diseases? Mary-Ann B. Shafer, MD; Robert H. Pantell, MD; Julius Schachter, PhD Objective:
More informationReceived 20 September 2006/Returned for modification 30 October 2006/Accepted 20 December 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2007, p. 747 751 Vol. 45, No. 3 0095-1137/07/$08.00 0 doi:10.1128/jcm.01956-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Characteristics
More informationHead-to-Head Evaluation of Five Chlamydia Tests Relative to a Quality-Assured Culture Standard
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1999, p. 681 685 Vol. 37, No. 3 0095-1137/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Head-to-Head Evaluation of Five Chlamydia
More informationPerformance of the Abbott RealTime CT/NG for Detection of
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2010, p. 3236 3243 Vol. 48, No. 9 0095-1137/10/$12.00 doi:10.1128/jcm.01019-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Performance
More informationUPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH. Dr Arlo Upton Clinical Microbiologist Labtests Auckland
UPDATE MOLECULAR DIAGNOSTICS IN SEXUAL HEALTH Dr Arlo Upton Clinical Microbiologist Labtests Auckland Talk outline Chlamydia trachomatis NAAT What does a positive test mean Interpreting low level positives
More informationPerformance of a Commercial Polymerase Chain Reaction Test for Endocervical Chlamydia trachomatis Infection in a University Hospital Population
Infectious Diseases in Obstetrics and Gynecology 6:224-229 (1998) (C) 1998 Wiley-Liss, Inc. Performance of a Commercial Polymerase Chain Reaction Test for Endocervical Chlamydia trachomatis Infection in
More informationAbout HPV. Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. Theree are more than 100 types of HPV, of which at
Cervical Cancer & HPV What is HPV Human papillomavirus (HPV) is a group of viruses that are extremely common worldwide. About HPV Theree are more than 100 types of HPV, of which at least 13 are cancer-causing
More informationCurrent Methods of Laboratory Diagnosis of Chlamydia trachomatis Infections
CLINICAL MICROBIOLOGY REVIEWS, Jan. 1997, p. 160 184 Vol. 10, No. 1 0893-8512/97/$04.00 0 Copyright 1997, American Society for Microbiology Current Methods of Laboratory Diagnosis of Chlamydia trachomatis
More informationMurex Chlamydia Verification Kit
1F83-01 E C06DK05GB Murex Chlamydia Verification Kit DK05 For the confirmatory testing of clinical samples reactive in Murex Chlamydia (1F82-01) Note Changes Highlighted 2005 Abbott / Printed in the UK
More informationBe sure! Your Power for Health. PelvoCheck CT/NG Your test kit for Chlamydia trachomatis screening and Neisseria gonorrhoeae infections
Your Power for Health Laboratory Information CT/NG DNA-Chip Be sure! Your test kit for Chlamydia trachomatis screening and Neisseria gonorrhoeae infections is part of the ocheck product line from Greiner
More informationBrowning M R, Corden S, Mitchell B, Westmoreland D. Setting The setting was a clinical laboratory. The economic study was conducted in the UK.
Screening for Chlamydia trachomatis infection using the BDProbeTec ET Chlamydia trachomatis amplified DNA assay on urine in a GUM clinic setting: a simple, fast and costeffective alternative Browning M
More informationNIH Public Access Author Manuscript Sex Transm Infect. Author manuscript; available in PMC 2013 June 04.
NIH Public Access Author Manuscript Published in final edited form as: Sex Transm Infect. 2013 June ; 89(4): 305 307. doi:10.1136/sextrans-2012-050686. Comparison of self-obtained penile-meatal swabs to
More informationEvaluation of the Digene Hybrid Capture II Assay with the Rapid Capture System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2002, p. 3558 3564 Vol. 40, No. 10 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.10.3558 3564.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationWomen by testing SurePath Liquid-Based Pap Specimens in APTIMA Assays ACCEPTED. Peter D Ascoli 5, Mark Martens 6
JCM Accepts, published online ahead of print on 20 June 2007 J. Clin. Microbiol. doi:10.1128/jcm.00013-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationCMV FEP ALA For nucleic acid amplification of CMV DNA and Fluorescence detection with End Point analysis (FEP) on Aladin (Sacace)
REF TV7-00FRT VER 3.0.06 CMV FEP ALA For nucleic acid amplification of CMV DNA and Fluorescence detection with End Point analysis (FEP) on Aladin (Sacace) Key to symbols used REF List Number Store at 2-8
More information/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.
JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2001, p. 1429 1435 Vol. 39, No. 4 0095-1137/01/$04.00 0 DOI: 10.1128/JCM.39.4.1429 1435.2001 Copyright 2001, American Society for Microbiology. All Rights Reserved.
More informationPerformance of the Abbott RealTime CT/NG for the Detection of Chlamydia. trachomatis and Neisseria gonorrhoeae
JCM Accepts, published online ahead of print on 28 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01019-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More information6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?
BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection
More informationNIH Public Access Author Manuscript Sex Transm Dis. Author manuscript; available in PMC 2009 July 16.
NIH Public Access Author Manuscript Published in final edited form as: Sex Transm Dis. 2008 July ; 35(7): 649 655. doi:10.1097/olq.0b013e31816ddb9a. Cost-Effectiveness of Screening Strategies for Chlamydia
More informationRecommendations for Laboratory Testing for Chlamydia trachomatis
Recommendations for Laboratory Testing for Chlamydia trachomatis Centers for Disease Control and Prevention Diagnostic test manufacturers have introduced a variety of nonculture tests for chlamydia, including
More informationThe epidemiology of Chlamydia trachomatis infection. Chlamydia trachomatis Infection in Asymptomatic Men. Background
Chlamydia trachomatis Infection in Asymptomatic Men D. Scott LaMontagne, MPH, David N. Fine, PhD, Jeanne M. Marrazzo, MD, MPH Background: Methods: Results: Conclusions: The epidemiology of Chlamydia trachomatis
More informationAPTIMA Combo 2 Testing Detected Additional Cases of Neisseria. gonorrhoeae in Men and Women in Community Settings. * Corresponding Author at:
JCM Accepts, published online ahead of print on 16 March 2011 J. Clin. Microbiol. doi:10.1128/jcm.02062-10 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationChlamydia Trachomatis IgA
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationReceived 13 August 2001/Returned for modification 22 November 2001/Accepted 24 January 2002
JOURNAL OF CLINICAL MICROBIOLOGY, May 2002, p. 1749 1754 Vol. 40, No. 5 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.5.1749 1754.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationT he organisms Chlamydia trachomatis and Neisseria gonorrhoeae
458 MYCOPLASMA GENITALIUM Mycoplasma genitalium: prevalence, clinical significance, and transmission C Anagrius, B Loré, J S Jensen... See end of article for authors affiliations... Correspondence to:
More informationendocervical, urethral, rectal, and pharyngeal
Genitourin Med 1997;73:493-497 Original article Department of Infectious Diseases, Aarhus University Hospital, PP rumsgade 11, DK- 8 Aarhus C, L stergaard Department of Dermato-Venerology, University of
More informationNoninvasive screening for genital chlamydial infections in asymptomatic men: Strategies and costs using a urine PCR assay
ORIGINAL ARTICLE Noninvasive screening for genital chlamydial infections in asymptomatic men: Strategies and costs using a urine PCR assay Rosanna W Peeling PhD 1, Baldwin Toye MD 2,4, Peter Jessamine
More informationChlamydia trachomatis Genotypes and the Swedish New Variant among Urogenital Chlamydia trachomatis Strains in Finland
Hindawi Publishing Corporation Infectious Diseases in Obstetrics and Gynecology Volume 2011, Article ID 481890, 6 pages doi:10.1155/2011/481890 Research Article Chlamydia trachomatis Genotypes and the
More informationChlamydia trachomatis in sexually active teenage
Genitourin Med 1991;67:317-321 Chlamydia trachomatis in sexually active teenage girls. Factors related to genital chlamydial infection: A prospective study V A Rahm, V Odlind, R Pettersson Abstract The
More informationChlamydia trachomatis (CHLa)Test Kit
Chlamydia trachomatis (CHLa)Test Kit Instructions For Use Format: Cassette Specimen: Urethral/Genital Swab Catalog Number: VEL-001-CHLa * Please read the instructions carefully before use INTENDED USE
More informationLOCUS MEDICUS SA, 2012
The determination of endometrial status by testing menstruation tissue is an internationally patented clinical test (European Patent 1395670). LOCUS MEDICUS S.A., Athens, Greece is the sole clinical laboratory
More informationDX CT/NG/MG AUTO ASSAY
DX CT/NG/MG AUTO ASSAY 5 x 96 37015 Direct detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium by Real-Time PCR * 881106-2013/02 Table of Content 1- INTENDED USE...3 2-
More informationCHLAMYDIA TRACHOMATIS INFECTIONS IN FEMALE MILITARY RECRUITS
CHLAMYDIA TRACHOMATIS INFECTIONS IN FEMALE MILITARY RECRUITS CHLAMYDIA TRACHOMATIS INFECTIONS IN FEMALE MILITARY RECRUITS CHARLOTTE A. GAYDOS, DR.P.H., M. RENE HOWELL, M.S., BARBARA PARE, M.S., KATHRYN
More informationNew CT/GC Tests. CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009
CDC National Infertility Prevention Project Laboratory Update Region II May 13-14, 2009 Richard Steece, Ph.D., D(ABMM) DrRSteece@aol.com New CT/GC Tests New Nucleic Acid Amplification Tests (NAATs) for
More informationENG MYCO WELL D- ONE REV. 1.UN 29/09/2016 REF. MS01283 REF. MS01321 (COMPLETE KIT)
ENG MYCO WELL D- ONE MYCO WELL D-ONE System for the presumptive identification and antimicrobial susceptibility test of urogenital mycoplasmas, Gardnerella vaginalis, Trichomonas vaginalis, Candida albicans
More informationVulvovaginal-Swab or First-Catch Urine Specimen To Detect Chlamydia trachomatis in Women in a Community Setting?
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2006, p. 4389 4394 Vol. 44, No. 12 0095-1137/06/$08.00 0 doi:10.1128/jcm.01060-06 Vulvovaginal-Swab or First-Catch Urine Specimen To Detect Chlamydia trachomatis
More informationPart II Serology Caroline Bax BW.indd 55 Caroline Bax BW.indd : :17
Part II Serology part II Chapter 4 Comparison of serological assays for detection of Chlamydia trachomatis antibodies in different groups of obstetrical and gynaecological patients C.J. Bax J.A.E.M. Mutsaers
More informationMitochondrial DNA Isolation Kit
Mitochondrial DNA Isolation Kit Catalog Number KA0895 50 assays Version: 01 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 General Information... 4 Materials
More informationOBJECTIVES. Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections
Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections OBJECTIVES I. Appreciate the changing epidemiology of trichomoniasis and clinician ordering patterns on the basis of improved
More informationPerformance of the Abbott Real Time CT/NG assay in urines and cervicovaginal samples from Senegal
Brief Original Article Performance of the Abbott Real Time CT/NG assay in urines and cervicovaginal samples from Senegal Sokhna B Gueye 1, Halimatou Diop-Ndiaye 1, Aliou Gningue 1, Ousseynou Ndiaye 1,
More informationEmerging Laboratory Diagnostic Options for Sexually-transmitted Infections
Emerging Laboratory Diagnostic Options for Sexually-transmitted Infections Erik Munson Wheaton Franciscan Laboratory Marquette University Milwaukee, Wisconsin 1 OBJECTIVES I. Appreciate the changing epidemiology
More informationABIOpure TM Viral (version 2.0)
ABIOpure TM Viral (version 2.0) DNA/RNA Extraction Handbook Cat No: M561VT50 FOR RESEARCH USE ONLY Table of Contents Contents Page Kit Components 3 Precautions 3 Stability & Storage 4 General Description
More informationReceived 5 March 2007/Returned for modification 17 May 2007/Accepted 11 June 2007
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2007, p. 2793 2797 Vol. 45, No. 9 0095-1137/07/$08.00 0 doi:10.1128/jcm.00491-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Evaluation
More informationE.Z.N.A. SQ Blood DNA Kit II. Table of Contents
E.Z.N.A. SQ Blood DNA Kit II Table of Contents Introduction and Overview...2 Kit Contents/Storage and Stability...3 Blood Storage and DNA Yield...4 Preparing Reagents...5 100-500 μl Whole Blood Protocol...6
More informationNuclear Extraction Kit
Nuclear Extraction Kit Catalog Number KA1346 50 assays Version: 07 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Principle of the Assay... 3 General Information... 4
More informationRapid Diagnosis of Chlamydial Infection in Young Women at Reproductive Age
Feb. 2012, Volume 9, No. 2 (Serial No. 87), pp. 112 116 Journal of US-China Medical Science, ISSN 1548-6648, USA D DAVID PUBLISHING Rapid Diagnosis of Chlamydial Infection in Young Women at Reproductive
More informationHuman HBcAb IgM ELISA kit
Human HBcAb IgM ELISA kit Catalog number: NR-R10163 (96 wells) The kit is designed to qualitatively detect HBcAb IgM in human serum or plasma. FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PURPOSES
More informationLumino Firefly Luciferase Assay
G-Biosciences 1-800-628-7730 1-314-991-6034 technical@gbiosciences.com A Geno Technology, Inc. (USA) brand name Lumino Firefly Luciferase Assay (Cat. # 786 1267, 786 1268) think proteins! think G-Biosciences
More information